{"title":"Advances in Radiation Oncology Top Downloaded Articles of 2025","authors":"Rachel B. Jimenez MD","doi":"10.1016/j.adro.2026.102109","DOIUrl":"10.1016/j.adro.2026.102109","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 10","pages":"Article 102109"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149211124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"ASTRO’s Advances in Radiation Oncology Top Reviewers for 2025","authors":"Rachel B. Jimenez MD","doi":"10.1016/j.adro.2026.102182","DOIUrl":"10.1016/j.adro.2026.102182","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 10","pages":"Article 102182"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149211125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gopal K. Bajaj MD, MBA, FASTRO, Jarad Martin PhD, DMed, MB, ChB, Clifford G. Robinson MD, Markus Bredel MD, PhD, Kenneth Merrell MD, Evan Thomas MD, PhD, John P. Plastaras MD, PhD, Jessica Schuster MD, Emily Wilson BS
{"title":"Beyond Cancer: Functional Radiation Medicine at an Inflection Point","authors":"Gopal K. Bajaj MD, MBA, FASTRO, Jarad Martin PhD, DMed, MB, ChB, Clifford G. Robinson MD, Markus Bredel MD, PhD, Kenneth Merrell MD, Evan Thomas MD, PhD, John P. Plastaras MD, PhD, Jessica Schuster MD, Emily Wilson BS","doi":"10.1016/j.adro.2026.102162","DOIUrl":"10.1016/j.adro.2026.102162","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 9","pages":"Article 102162"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Computer Tomography-Based Target Volume Delineation and Clinical Outcomes of Low-Dose Radiation Therapy for Knee Osteoarthritis","authors":"Yueh-Feng Lu MD, PhD, Eva Yu-Hsuan Chuang MD, Zhao-Yu Hsieh MD, Kai-Xuan Lim MD, Pei-Wei Shueng MD, Chen-Xiong Hsu MD, PhD, Deng-Yu Kuo MD, Pei-Yu Hou MD, PhD, Chih-Hung Chang MD, PhD, Chen-Hsi Hsieh MD, PhD","doi":"10.1016/j.adro.2026.102120","DOIUrl":"10.1016/j.adro.2026.102120","url":null,"abstract":"<div><h3>Purpose</h3><div>Low-dose radiation therapy is a noninvasive and cost-effective treatment modality used to alleviate pain and improve joint function in patients with knee osteoarthritis. However, standardized guidelines for computed tomography (CT)-based target delineation remain limited. This study aims to evaluate the feasibility and safety of low-dose radiation therapy using a CT-based, anatomy-guided clinical target volume that incorporates both bony and soft tissue structures.</div></div><div>Low-dose radiation therapy is a noninvasive and cost-effective treatment modality used to alleviate pain and improve joint function in patients with knee osteoarthritis. However, standardized guidelines for computed tomography (CT)-based target delineation remain limited. This study aims to evaluate the feasibility and safety of low-dose radiation therapy using a CT-based, anatomy-guided clinical target volume that incorporates both bony and soft tissue structures.</div><div><h3>Methods and Materials</h3><div>We conducted a retrospective analysis of patients with knee osteoarthritis who received low-dose radiation therapy at our institution. The clinical target volume was delineated on simulation CT to encompass the entire knee joint. Patients received a total dose of 3 Gy, delivered in 6 fractions of 0.5 Gy each on nonconsecutive days. Pain was assessed using a 10-point visual analog scale (VAS) before treatment initiation and upon completion.</div></div><div>We conducted a retrospective analysis of patients with knee osteoarthritis who received low-dose radiation therapy at our institution. The clinical target volume was delineated on simulation CT to encompass the entire knee joint. Patients received a total dose of 3 Gy, delivered in 6 fractions of 0.5 Gy each on nonconsecutive days. Pain was assessed using a 10-point visual analog scale (VAS) before treatment initiation and upon completion.</div><div><h3>Results</h3><div>A total of 37 patients (median age 69 years; 17 men and 20 women) received treatment across 71 knee sites. The median follow-up was 4.2 months. The median pretreatment VAS score was 6 (range, 4-10), significantly decreasing to 2 (range, 0-5) posttreatment (<em>P</em> < .001). At a minimum follow-up of 2 months, no acute toxicities of grade ≥2 were observed. In a representative case, CT-based delineation enabled inclusion of suprapatellar recess effusion extending beyond conventional field margins, illustrating the potential for improved anatomical coverage.</div></div><div>A total of 37 patients (median age 69 years; 17 men and 20 women) received treatment across 71 knee sites. The median follow-up was 4.2 months. The median pretreatment VAS score was 6 (range, 4-10), significantly decreasing to 2 (range, 0-5) posttreatment (<em>P</em> < .001). At a minimum follow-up of 2 months, no acute toxicities of grade ≥2 were observed. In a representative case, CT-based delineation enabled inclusion of suprapatellar recess eff","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 9","pages":"Article 102120"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily Schwartz, Michael Anderson MD, Russell Nevins MD, Kelsey Moakler PA-C, Andrew Cohen MD, Michael Sinopoli MD, Samual Francis MD, Bradley Newby CMD, Matthew Schwartz MD
{"title":"Low-Dose Radiation Therapy for Peripheral Joint Osteoarthritis: Early United States Community Experience With Pain, Function, and Medication Outcomes","authors":"Emily Schwartz, Michael Anderson MD, Russell Nevins MD, Kelsey Moakler PA-C, Andrew Cohen MD, Michael Sinopoli MD, Samual Francis MD, Bradley Newby CMD, Matthew Schwartz MD","doi":"10.1016/j.adro.2026.102073","DOIUrl":"10.1016/j.adro.2026.102073","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to evaluate the real-world effectiveness and feasibility of low-dose radiation therapy (LDRT) for peripheral joint osteoarthritis (OA) in a United States community oncology setting, focusing on pain, function, and analgesic outcomes.</div></div><div>This study aimed to evaluate the real-world effectiveness and feasibility of low-dose radiation therapy (LDRT) for peripheral joint osteoarthritis (OA) in a United States community oncology setting, focusing on pain, function, and analgesic outcomes.</div><div><h3>Methods and Materials</h3><div>We retrospectively analyzed 30 consecutive patients (55 joints) treated with LDRT (3 Gy in 6 fractions; 0.5 Gy per fraction) for OA. Pain was assessed using a 0 to 10 numeric rating scale. Global improvement was captured with the von Pannewitz score (0-4; lower = greater improvement). Analgesic change was abstracted from the medical record. Paired tests compared pre- and posttreatment outcomes.</div></div><div>We retrospectively analyzed 30 consecutive patients (55 joints) treated with LDRT (3 Gy in 6 fractions; 0.5 Gy per fraction) for OA. Pain was assessed using a 0 to 10 numeric rating scale. Global improvement was captured with the von Pannewitz score (0-4; lower = greater improvement). Analgesic change was abstracted from the medical record. Paired tests compared pre- and posttreatment outcomes.</div><div><h3>Results</h3><div>Mean baseline pain was 8.1 ± 1.4, improving to 3.5 ± 1.7 at early follow-up (Δ−4.6; <em>P</em> < .001). von Pannewitz score indicated improvement in 92% of treated joints. Twenty-three percent of patients reduced analgesic use; none required analgesic escalation. All patients completed treatment without interruptions, and no acute toxicities were recorded.</div></div><div>Mean baseline pain was 8.1 ± 1.4, improving to 3.5 ± 1.7 at early follow-up (Δ−4.6; <em>P</em> < .001). von Pannewitz score indicated improvement in 92% of treated joints. Twenty-three percent of patients reduced analgesic use; none required analgesic escalation. All patients completed treatment without interruptions, and no acute toxicities were recorded.</div><div><h3>Conclusions</h3><div>In a community oncology setting, LDRT was feasible and associated with clinically meaningful reductions in pain and analgesic use for peripheral joint OA. These findings support prospective trials to validate benefits and define optimal patient selection and retreatment strategies.</div></div><div>In a community oncology setting, LDRT was feasible and associated with clinically meaningful reductions in pain and analgesic use for peripheral joint OA. These findings support prospective trials to validate benefits and define optimal patient selection and retreatment strategies.</div>","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 9","pages":"Article 102073"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ella Zhang BS, Patrick Oh MD, Tracy Shamas APRN, Huned S. Patwa MD, Kimberly L. Johung MD, PhD
{"title":"Radiation Therapy for Sialorrhea in Patients With Amyotrophic Lateral Sclerosis: A Case Series and Critical Review","authors":"Ella Zhang BS, Patrick Oh MD, Tracy Shamas APRN, Huned S. Patwa MD, Kimberly L. Johung MD, PhD","doi":"10.1016/j.adro.2026.102135","DOIUrl":"10.1016/j.adro.2026.102135","url":null,"abstract":"<div><h3>Purpose</h3><div>Radiation therapy (RT) for sialorrhea has historically used 3-dimensional techniques that broadly irradiate both major and minor salivary glands. However, some reports indicate that treatment of minor salivary glands may contribute to excessive xerostomia. In this retrospective case series, we assessed the efficacy and tolerability of oral-cavity-sparing volumetric modulated arc therapy (VMAT) and bilateral electron field radiation for sialorrhea in patients with amyotrophic lateral sclerosis (ALS) and reviewed the relevant literature.</div></div><div>Radiation therapy (RT) for sialorrhea has historically used 3-dimensional techniques that broadly irradiate both major and minor salivary glands. However, some reports indicate that treatment of minor salivary glands may contribute to excessive xerostomia. In this retrospective case series, we assessed the efficacy and tolerability of oral-cavity-sparing volumetric modulated arc therapy (VMAT) and bilateral electron field radiation for sialorrhea in patients with amyotrophic lateral sclerosis (ALS) and reviewed the relevant literature.</div><div><h3>Methods and Materials</h3><div>From 2014 to 2025, 6 patients with bulbar-onset ALS and medically refractory sialorrhea were treated with RT to the parotid and submandibular glands (20 Gy in 5 fractions) at a single institution. Five patients received VMAT with 6 MV photons, and one received bilateral 16 MeV electrons. Clinical response, medication use, toxicity, and dosimetry were assessed. A PubMed search using “sialorrhea,” “RT,” and “amyotrophic lateral sclerosis” was performed for the literature review.</div></div><div>From 2014 to 2025, 6 patients with bulbar-onset ALS and medically refractory sialorrhea were treated with RT to the parotid and submandibular glands (20 Gy in 5 fractions) at a single institution. Five patients received VMAT with 6 MV photons, and one received bilateral 16 MeV electrons. Clinical response, medication use, toxicity, and dosimetry were assessed. A PubMed search using “sialorrhea,” “RT,” and “amyotrophic lateral sclerosis” was performed for the literature review.</div><div><h3>Results</h3><div>At a median follow-up of 15.05 months (range, 3.0-61.7 months), 5 of 6 patients (83.3%) achieved symptomatic improvement, with an average 60% patient-reported reduction in salivation and ≥2 point improvement in ALS Functional Rating Scale saliva subscore. Two discontinued anticholinergics, and 1 achieved complete resolution for 3 years. Acute toxicities with VMAT were mild and self-limiting, most commonly parotitis and thickened secretions. The patient treated with electrons developed grade 2 mucositis, not observed with VMAT. Late toxicities, including xerostomia, were minimal and transient. Dosimetry showed higher larynx and oral cavity doses with electrons, whereas VMAT delivered slightly higher spinal cord doses. Critical literature review supported RT as an effective and well-tolerated intervention.</d","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 9","pages":"Article 102135"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jason Liu BS, Cody C. Green MD, George J. Haidukewych MD, Amish P. Shah PhD, Patrick Kelly MD, PhD, Justin Rineer MD
{"title":"Clinical and Patient-Reported Outcomes Following Total Knee Revision for Arthrofibrosis Using Modern Rotating Hinged Knee Arthroplasty and Preoperative Radiation Therapy: A Single-Institution Retrospective Analysis","authors":"Jason Liu BS, Cody C. Green MD, George J. Haidukewych MD, Amish P. Shah PhD, Patrick Kelly MD, PhD, Justin Rineer MD","doi":"10.1016/j.adro.2026.102110","DOIUrl":"10.1016/j.adro.2026.102110","url":null,"abstract":"<div><h3>Purpose</h3><div>Arthrofibrosis is a debilitating complication following total knee arthroplasty (TKA) characterized by excessive fibroproliferation leading to restricted range of motion (ROM) and impaired function. Radiation therapy (RT) has demonstrated efficacy in modulating fibroblast activity in benign conditions, yet patient-reported outcomes following RT-assisted management of arthrofibrosis remain poorly defined. This study evaluates clinical and patient-reported outcomes in patients undergoing revision TKA for severe arthrofibrosis augmented with preoperative RT.</div></div><div>Arthrofibrosis is a debilitating complication following total knee arthroplasty (TKA) characterized by excessive fibroproliferation leading to restricted range of motion (ROM) and impaired function. Radiation therapy (RT) has demonstrated efficacy in modulating fibroblast activity in benign conditions, yet patient-reported outcomes following RT-assisted management of arthrofibrosis remain poorly defined. This study evaluates clinical and patient-reported outcomes in patients undergoing revision TKA for severe arthrofibrosis augmented with preoperative RT.</div><div><h3>Methods and Materials</h3><div>In this retrospective study, patients undergoing revision TKA for severe arthrofibrosis with adjunctive preoperative RT between 2023 and 2025 were identified. All patients received a single fraction of 8.0 Gy external beam RT within 24 hours prior to surgery. Clinical outcomes included passive ROM measured preoperatively, at 6 weeks, and at final follow-up. Patient-reported outcomes were assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function, PROMIS Pain Interference, PROMIS Global Physical Health, and Knee injury and Osteoarthritis Outcome Score for Joint Replacement instruments. Paired <em>t</em> tests compared pre- and postoperative outcomes.</div></div><div>In this retrospective study, patients undergoing revision TKA for severe arthrofibrosis with adjunctive preoperative RT between 2023 and 2025 were identified. All patients received a single fraction of 8.0 Gy external beam RT within 24 hours prior to surgery. Clinical outcomes included passive ROM measured preoperatively, at 6 weeks, and at final follow-up. Patient-reported outcomes were assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function, PROMIS Pain Interference, PROMIS Global Physical Health, and Knee injury and Osteoarthritis Outcome Score for Joint Replacement instruments. Paired <em>t</em> tests compared pre- and postoperative outcomes.</div><div><h3>Results</h3><div>Thirteen patients were included with a mean follow-up of 19 weeks. Mean total arc of motion improved from 69.5° preoperatively to 94.5° at 6 weeks and 98.3° at final follow-up (<em>P</em> < .01). PROMIS Physical Function improved by a mean of 7.8 points (<em>P</em> = .013), PROMIS Pain Interference decreased by 10.1 points (<em>P</em> = .017","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 9","pages":"Article 102110"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joyce Kuo BS, Alice Jiang BA, Yi Peng Wang BS, Amy Ladd MD, Catherine Curtin MD, Jeffrey Yao MD, Sarah S. Donaldson MD, Susan M. Hiniker MD, Justin Oh MD
{"title":"Patient-Reported Outcomes After Radiation Therapy for Dupuytren’s Contracture","authors":"Joyce Kuo BS, Alice Jiang BA, Yi Peng Wang BS, Amy Ladd MD, Catherine Curtin MD, Jeffrey Yao MD, Sarah S. Donaldson MD, Susan M. Hiniker MD, Justin Oh MD","doi":"10.1016/j.adro.2026.102161","DOIUrl":"10.1016/j.adro.2026.102161","url":null,"abstract":"<div><h3>Purpose</h3><div>Dupuytren’s contracture (DC) is a fibroproliferative disorder that can result in functional impairment of the hand. Radiation therapy (RT) is used to prevent disease progression and sometimes as adjuvant therapy after surgeries and recurrences. However, comprehensive data on patient-reported efficacy are limited. This study aimed to assess patient-reported outcomes in patients with DC treated with primary and adjuvant RT.</div></div><div>Dupuytren’s contracture (DC) is a fibroproliferative disorder that can result in functional impairment of the hand. Radiation therapy (RT) is used to prevent disease progression and sometimes as adjuvant therapy after surgeries and recurrences. However, comprehensive data on patient-reported efficacy are limited. This study aimed to assess patient-reported outcomes in patients with DC treated with primary and adjuvant RT.</div><div><h3>Methods and Materials</h3><div>A single-institution retrospective study was conducted, including 22 patients treated with RT for DC between April 2017 and July 2022. Surveys to assess satisfaction, perceived effectiveness, and treatment burden used Likert scales and the post-RT Southampton Dupuytren’s Scoring Scheme. All patients received either 30 Gy in a split course or 21 Gy in continuous daily treatments.</div></div><div>A single-institution retrospective study was conducted, including 22 patients treated with RT for DC between April 2017 and July 2022. Surveys to assess satisfaction, perceived effectiveness, and treatment burden used Likert scales and the post-RT Southampton Dupuytren’s Scoring Scheme. All patients received either 30 Gy in a split course or 21 Gy in continuous daily treatments.</div><div><h3>Results</h3><div>Median follow-up was 4.3 years, and median age at diagnosis was 61 years. Sixty-three percent had undergone fasciectomy before RT. Seventy-seven percent expressed satisfaction with RT outcomes, and 68% perceived it as effective. Median post-RT Southampton Dupuytren’s Scoring Scheme score was 5 (IQR, 4-6), indicating mild functional limitations. Four patients (18%) experienced new nodules or cords, and only 1 patient (4.5%) required further surgery. Thirteen patients (59%) reported side effects from RT, most commonly mild dry skin. One patient developed severe dry skin, but there were no other severe toxicities or malignancies observed.</div></div><div>Median follow-up was 4.3 years, and median age at diagnosis was 61 years. Sixty-three percent had undergone fasciectomy before RT. Seventy-seven percent expressed satisfaction with RT outcomes, and 68% perceived it as effective. Median post-RT Southampton Dupuytren’s Scoring Scheme score was 5 (IQR, 4-6), indicating mild functional limitations. Four patients (18%) experienced new nodules or cords, and only 1 patient (4.5%) required further surgery. Thirteen patients (59%) reported side effects from RT, most commonly mild dry skin. One patient developed severe dry skin, but there were","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 9","pages":"Article 102161"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Renée Duvenage BMed, MD, Jacques D. Hill BHB, MBChB, FRANZCR
{"title":"External Beam Radiation Therapy for Granuloma Faciale: A Contemporary Approach and Clinical Lessons From a Refractory Case","authors":"Renée Duvenage BMed, MD, Jacques D. Hill BHB, MBChB, FRANZCR","doi":"10.1016/j.adro.2026.101994","DOIUrl":"10.1016/j.adro.2026.101994","url":null,"abstract":"","PeriodicalId":7390,"journal":{"name":"Advances in Radiation Oncology","volume":"11 9","pages":"Article 101994"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}